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Pulmonary mucormycosis is a rare life-threatening fungal infection associated with high mortality. We present the case of a 61-
year-old man with history of chronic lymphocytic leukemia who presented with fever and cough, eventually diagnosed with
pulmonary mucormycosis after right lung video-assisted thoracoscopic surgery. +e patient was successfully treated with
amphotericin B and right lung pneumonectomy; however, he later died from left lung pneumonia.
1. Introduction
Pulmonary mucormycosis is a rare but life-threatening,
rapidly progressive infection that occurs in immunocom-
promised patients withmortality as high as 76% that is 10–50
times less likely than aspergillus or candida infection [1–3].
Early clinical diagnosis can be delayed in the setting of
concomitant infections such as pneumonia and bacteremia.
However, prompt diagnosis is critical to initiate early ag-
gressive management. We report the case of a patient with
chronic lymphocytic leukemia (CLL) with resultant neu-
tropenia undergoing chemotherapy diagnosed with pul-
monary mucormycosis.
2. Case Description
A 61-year-old man with past medical history of sarcoidosis,
deep vein thrombosis on rivaroxaban, and CLL treated with
bendamustine and rituximab complicated by neutropenia
presented to the outpatient office with (four) days of fevers
and scant hemoptysis. On physical exam, patient had
temperature of 38.4°C, blood pressure of 128/60mm Hg,
respirations of 18 per minute, heart rate of 92 beats per
minute, and oxygen saturation of 96% in room air. Lung
sounds were diminished bilaterally. His white blood cell
count was 88,200/µL with absolute neutrophil count 1900/UI
(2.15%), hemoglobin level 7.4 g/dL (decreased from 8.8 g/dL
three weeks prior), and platelet count 291,000/µL. Chest
radiograph revealed a large mass-like consolidation in the
right upper lobe, which was new compared to computerized
tomography (CT) imaging two months prior.
+e patient was transported to the hospital, admitted for
sepsis secondary to community-acquired pneumonia, and
initiated on intravenous broad-spectrum antibiotics. CT
chest was obtained due to concern for hemorrhage on
ibrutinib. It revealed a mass-like consolidation in the right
upper lobe along with diffuse nodules and multifocal air-
space disease suspicious for invasive aspergillosis (Figure 1).
Aspergillus antibody was obtained; however, empiric anti-
fungal therapy was deferred while blood cultures grew
S. pneumoniae. +e patient failed to improve clinically
prompting bronchoscopy evaluation, which identified pu-
rulent airway secretions. Bronchial aspirate cytology was
unrevealing, and specimens were sent for further microbi-
ology testing. +e patient continued to decline. CT-guided
needle biopsy of the consolidation established presence of
scattered Gomori methenamine silver (GMS) and periodic
acid-Schiff (PAS) positive structures suggestive of fungal
etiology. So, voriconazole was started.
Repeat chest CT demonstrated worsening airspace dis-
ease, and the patient underwent video-assisted thoraco-
scopic surgery (VATS) with right upper and middle lobe
wedge resection. VATS revealed severe dense adhesions,
thickened and necrotic pleura, and the lung was found to be
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consolidated, hard, and hepatized with necrosis (Figure 2).
Preliminary cultures were negative but eventually grew
Rhizopus species. Since voriconazole is not effective against
Rhizopus, it was discontinued and the patient was started on
amphotericin B liposomal 5mg/kg/24 hours. Six days after
VATS, histopathologic analysis revealed presence of non-
septate fungal hyphae with right-angle branching suggestive
of mucormycosis. Patient failed to improve after VATS;
thus, patient underwent right pneumonectomy with sub-
sequent clinical improvement. He was initially discharged to
rehab eight days after pneumonectomy (43 days after ad-
mission) with plan for a 14-day course of amphotericin B
after pneumonectomy followed by initiation of pos-
aconazole as recommended per infectious disease specialist.
Unfortunately, the patient returned to the hospital eleven
days after discharge with complications of wound de-
hiscence and bronchocutaneous fistula formation that grew
Rhizopus. +us, patient’s amphotericin B course was pro-
longed to a total of 46 days after pneumonectomy after
which he was transitioned to posaconazole. +is gentleman
unfortunately suffered from further wound complications,
VRE infection, and was unable to return home, and dis-
charged to a nursing facility several months later. Patient
returned to the hospital from nursing home with left lung
pneumonia positive for rhinovirus-enterovirus and eventually
passed away seven months later due to complications during
that admission.
3. Discussion
Mucormycosis can take several forms including rhinoc-
erebral, pulmonary, cutaneous, gastrointestinal, and dis-
seminated disease [2]. Risk factors include diabetes mellitus,
hematologic malignancy, receiving hematopoietic stem cell
transplant, deferoxamine therapy, injection drug use, and
trauma or burns [1–4]. Pulmonary infection is most com-
monly found in patients with hematologic malignancy, as
was the case in our patient [1, 2, 5]. Additional risk factors for
pulmonary infection include male gender, neutropenia,
chronic steroid use, underlying rheumatologic disorders,
and voriconazole prophylaxis in patients undergoing che-
motherapy [2, 5–7]. Bendamustine and rituximab have been
associated with impaired lymphocyte recovery in patients
with CLL, and both agents have also been associated with an
increased risk of serious opportunistic infections [8, 9]. +us,
in the case of our patient, these chemotherapy agents may also
have contributed to the development of mucormycosis.
+e symptoms are typically nonspecific even in later
stages of infection, and co-infection can further complicate
diagnosis. Infection most commonly presents as acute-onset
(a) (b)
(c)
Figure 1: CT chest from day of admission (a), day of fine needle biopsy (b), and prior to VATS (c).
2 Case Reports in Infectious Diseases
high fever with nonproductive cough, dyspnea, or chest pain
that is unresponsive to broad-spectrum antibiotics [2, 4, 7].
Radiological manifestations are mostly nonspecific, and
disease tends to impact the upper lobes [4]. Findings on
imaging that suggest pulmonary mucormycosis are greater
than ten nodules, presence of pleural effusion, and a reverse
halo sign on CTchest [2, 10, 11]. Bourcier et al. found that the
presence of the reverse halo sign is more common in
neutropenic patients with pulmonary mucormycosis, enough
for them to suggest initiation of mucormycosis antifungal
therapy based on the presence of this sign [10]. Sputum se-
cretions and broncheoalveolar lavage cultures are notoriously
insensitive for detection of mucormycosis, and even cultures
from fine needle aspiration often fail to grow [4, 5]. +e
sensitivity can be improved by placing tissue sections directly
on a culture plate without prior grinding or homogenizing the
material, as it can disrupt the fungal structure [4, 5]. Colonies
can take three to five days to grow. Diagnosis is achieved by
demonstrating hyphae with variable width (from 6 to 25µm),
zero or sparse septations, irregular ribbon-like appearance, and
nonpigmented and wide-angle bifurcations including 90-de-
gree angles. PAS and GMS stains must be used to properly
visualize the hyphae [5]. Mucorales PCR has been shown to be
useful for confirmation of the diagnosis of mucormycosis;
however, it requires further investigation as a method of im-
proving detection of mucormycosis in the clinical setting [12].
3.1. Management. Pulmonary mucormycosis has a poor
prognosis. Patientswhoundergo combination of pharmacological
and surgical management have been shown to do better com-
pared to either treatment alone [4, 12, 13]. +e drug of choice for
initial therapy is amphotericin B while posaconazole or isavu-
conazole can be used for step-down therapy [14, 15]. Correction of
underlying predisposing conditions, such as acidosis or neu-
tropenia, and discontinuation of steroids or iron-chelating agents
is required. Posaconazole has been reported as an effective salvage
therapy in studies [14, 16]. Cornely et al. also showed that pos-
aconazole improved survival and more effectively prevented in-
vasive fungal infections than fluconazole or itraconazole in
patients with hematologic malignancy undergoing chemotherapy
[17].+us, to prevent severemucor infections, posaconazole could
potentially be considered for prophylaxis in patients with he-
matologicmalignancy, especially those undergoing chemotherapy
who are at risk for neutropenia.
4. Conclusion
Pulmonary mucormycosis is a rare but potentially fatal
fungal infection that occurs in immunocompromised pa-
tients, most commonly in those with hematologic malig-
nancy [1, 4]. Early recognition is crucial for prompt initiation
of pharmacological and surgical comanagement to improve
high rates of associated morbidity and mortality [2, 12]. Due
to its nonspecific presentation, diagnosis is often difficult.
However, suspicion and early initiation of therapy should be
considered in immunosuppressed patients, especially neu-
tropenic patients with hematologic malignancy, who present
with fever and cough that is unresponsive to broad-spectrum
antibiotics.
(a) (b)
(c)
Figure 2: Histologic sections of pulmonary parenchyma showing prominent necrosis and angioinvasion by fungal species. Fungal hyphal
forms noted in lumen and wall of pulmonary vessel (a). Intravascular broad and ribbon-like hyphal forms with right-angle branching and
absence of septations, morphologically consistent with zygomycetic infection (hematoxylin/eosin stain (b); GMS staining (c)).
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